Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
September 29, 2017 at 16:52 PM EDT
The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s positive Fragile X trial results with marked ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.